William Jones - Nov 25, 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd. (BHVN)

Role: CCO-Migraine & Common Disease
Signature: /s/ Jim Engelhart, Attorney-in-Fact
Stock symbol: BHVN
Transactions as of: Nov 25, 2021
Transactions value $: -$150,793
Form type: 4
Date filed: 11/26/2021, 03:32 PM
Next filing: Jan 7, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BHVN	Common Shares	Options Exercise	$0	+3K	+42.09%	$0.00	10.1K	Nov 25, 2021	Direct
transaction	BHVN	Common Shares	Tax liability	-$151K	-1.31K	-12.89%	$115.55^*	8.82K	Nov 25, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BHVN	Restricted Share Unit Award	Options Exercise	$0	-3K	-50%	$0.00	3K	Nov 25, 2021	Common Shares	3K		Direct	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
F2	Each restricted share unit represents the contingent right to receive one common share of the issuer.
F3	The reporting person was granted 12,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date.
F4	Not applicable.